Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Hims & Hers Health CFO talks GLP-1s, earnings
11:20am, Tuesday, 05'th Nov 2024
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, help
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
10:30pm, Monday, 04'th Nov 2024
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
06:28pm, Monday, 04'th Nov 2024
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-l
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model
Global Partners LP Completes Acquisition of East Providence Liquid Energy Terminal
11:45am, Friday, 01'st Nov 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE:GLP) (“Global” or the “Partnership”) announced today that it has successfully completed the acquisition of a liquid energy terminal in
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
10:45am, Sunday, 27'th Oct 2024
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
12:11pm, Thursday, 24'th Oct 2024
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
09:10am, Thursday, 24'th Oct 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:L
Global Partners LP to Host Third-Quarter 2024 Financial Results Conference Call on November 8, 2024
08:30am, Thursday, 24'th Oct 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that it will release its third-quarter 2024 financial results before the market opens on Friday,
Global Partners Declares Third-Quarter 2024 Cash Distribution of $0.7300 on Common Units
08:30am, Wednesday, 23'rd Oct 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared a cash distribut
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
02:07pm, Tuesday, 22'nd Oct 2024
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analys
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
09:20am, Tuesday, 22'nd Oct 2024
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight r
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
08:45am, Thursday, 17'th Oct 2024
Novartis is taking a more calculated and strategic approach to its growth.
Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weigh
